ClinicalTrials.Veeva

Find clinical trials for Melanoma in Roma, Lazio

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Roma, Lazio, ITA:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Rome, Italy and 22 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Roma, Italy and 70 other locations

Locations recently updated

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Roma, Italy and 105 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Roma, Italy and 227 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Roma, Italy and 154 other locations

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Enrolling
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Rome, Roma, Italy and 62 other locations

Locations recently updated

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling
Melanoma
Drug: Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Roma, Italy and 84 other locations

of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...

Active, not recruiting
Melanoma
Drug: Ceralasertib
Biological: Durvalumab

Phase 2

AstraZeneca
AstraZeneca

Roma, Italy and 63 other locations

antigen (HLA)-A*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotini...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Roma, Italy and 62 other locations

patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...

Active, not recruiting
Melanoma Stage IV
Melanoma Stage III
Biological: BNT111
Biological: Cemiplimab

Phase 2

BioNTech
BioNTech

Rome, Italy and 52 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems